公开(公告)号：US20160340655A1

公开(公告)日：2016-11-24

申请号：US15022280

申请日：2014-09-15

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Rony SEGER ,  Alexander PLOTNIKOV

IPC: C12N9/12

CPC classification number: C12N9/12 ,  A61K38/00 ,  A61K38/12 ,  A61K47/64 ,  C12N9/1205 ,  C12Y207/11 ,  C12Y207/11024

Abstract: An isolated peptide being no longer than 20 amino acids comprising a sequence at least 95% homologous to the sequence GQLNHILGILGX1PX2QED (SEQ ID NO: 4), wherein X1 and X2 are any amino acid, the peptide being capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus.

Abstract translation: 分离的肽不超过20个氨基酸，其包含与序列GQLNHILGILGX1PX2QED（SEQ ID NO：4）至少95％同源的序列，其中X1和X2是任何氨基酸，该肽能够预防细胞外信号调节激酶1 / 2（ERK）易位进入细胞核。

公开(公告)号：US20160324975A1

公开(公告)日：2016-11-10

申请号：US15216870

申请日：2016-07-22

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Yoram SHECHTER ,  Matityahu FRIDKIN ,  Haim TSUBERY

IPC: A61K47/48 ,  A61K38/27 ,  A61K38/28 ,  A61K38/22 ,  A61K38/21 ,  A61K31/7036

CPC classification number: A61K47/60 ,  A61K31/7036 ,  A61K38/1709 ,  A61K38/212 ,  A61K38/22 ,  A61K38/2242 ,  A61K38/2278 ,  A61K38/26 ,  A61K38/27 ,  A61K38/28 ,  A61K47/54 ,  A61K47/545 ,  C07D207/404 ,  C07D207/416 ,  C07D207/452 ,  C07D403/12

Abstract: Reversible pegylated drugs are provided by derivatization of free functional groups of the drug selected from amino, hydroxyl, mercapto, phosphate and/or carboxyl with groups sensitive to mild basic conditions such as 9-fluorenylmethoxycarbonyl (Fmoc) or 2-sulfo-9-fluorenylmethoxycarbonyl (FMS), to which group a PEG moiety is attached. In these pegylated drugs, the PEG moiety and the drug residue are not linked directly to each other, but rather both residues are linked to different positions of the scaffold Fmoc or FMS structure that is highly sensitive to bases and is removable under physiological conditions. The drugs are preferably drugs containing an amino group, most preferably peptides and proteins of low or medium molecular weight. Similar molecules are provided wherein a protein carrier or another polymer carrier replaces the PEG moiety.

公开(公告)号：US09469907B2

公开(公告)日：2016-10-18

申请号：US14493111

申请日：2014-09-22

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Igor Lubomirsky ,  Valery Kaplan

IPC: C25B13/02 ,  C25B1/02 ,  C25B11/04 ,  C25B11/12 ,  C25B1/00 ,  C10G2/00

CPC classification number: C25B1/02 ,  C10G2/30 ,  C25B1/00 ,  C25B11/04 ,  C25B11/12 ,  C25B13/02

Abstract: The present invention relates to an electrolytic process, methods and apparatus for the preparation of carbon monoxide and in particular to electrolysis of molten carbonates to yield carbon monoxide which may be used for chemical storage of electrical energy and further as chemical feedstock for other organic products.

Abstract translation: 本发明涉及一种用于制备一氧化碳的电解方法，方法和装置，特别是电解熔融碳酸盐以产生一氧化碳，其可用于电能的化学储存，并且还用作其它有机产物的化学原料。

公开(公告)号：US20160264412A1

公开(公告)日：2016-09-15

申请号：US15031749

申请日：2014-10-28

Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

Inventor： Ronny NEUMANN ,  Bidyut-Bikash SARMA

IPC: C01B3/16 ,  C25B1/02 ,  C10K3/06 ,  C07C51/235 ,  C01B3/02 ,  B01J27/199

CPC classification number: C01B3/16 ,  B01J27/199 ,  C01B3/02 ,  C01B2203/0283 ,  C01B2203/1041 ,  C07C51/235 ,  C10G1/065 ,  C10G3/44 ,  C10K3/04 ,  C10K3/06 ,  C25B1/00 ,  C25B1/02 ,  Y02E60/366 ,  Y02P30/20

Abstract: The present invention relates to methods of preparing carbon monoxide (CO) and hydrogen (H2) by reacting biomass, a biomass component (e.g., lignin, ligno-cellulose, cellulose, hemiceullose or combination thereof) or a carbohydrate from any source with a polyoxometalate catalyst such as H5PV2Mo10O40, or solvates thereof, in the presence of a concentrated acid, under conditions sufficient to yield carbon monoxide (CO); followed by electrochemical release of hydrogen (H2). The carbon monoxide (CO) and hydrogen (H2) may be combined in any desired proportion to yield synthesis gas (Syngas). The present invention further relates to methods for preparing H2, CO and formic acid/formaldehyde from biomass, a biomass component and/or from carbohydrates.

Abstract translation: 本发明涉及通过生物质，生物质成分（例如木质素，木质纤维素，纤维素，半纤维素或其组合）或来自任何来源的碳水化合物与多金属氧酸盐反应来制备一氧化碳（CO）和氢（H 2）的方法 催化剂如H5PV2Mo10O40或其溶剂合物，在浓酸存在下，在足以产生一氧化碳（CO）的条件下; 然后电化学释放氢（H2）。 一氧化碳（CO）和氢（H 2）可以以任何所需比例组合以产生合成气（合成气）。 本发明还涉及从生物质，生物质成分和/或碳水化合物制备H 2，CO和甲酸/甲醛的方法。

公开(公告)号：US20160263166A1

公开(公告)日：2016-09-15

申请号：US15030650

申请日：2015-04-28

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Eran ELINAV ,  Eran SEGAL

IPC: A61K35/741 ,  C12Q1/02

CPC classification number: A61K35/741 ,  A61B5/411 ,  A61K35/66 ,  C12Q1/025 ,  C12Q1/04 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/68 ,  G01N2570/00

Abstract: A method of determining tolerance to an agent in a healthy subject is disclosed. The method comprises: (a) determining a signature of a microbiome in a sample of the healthy subject who has been subjected to the agent or condition; and (b) comparing the signature of the microbiome of the healthy subject to at least one reference signature of a pathological microbiome, wherein when the signature of the microbiome of the healthy subject is statistically significantly similar to the reference signature of the pathological microbiome, it is indicative that the healthy subject is intolerant to the agent.

公开(公告)号：US20160213762A1

公开(公告)日：2016-07-28

申请号：US15095300

申请日：2016-04-11

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Michal EISENBACH-SCHWARTZ ,  Jonathan KIPNIS

IPC: A61K39/00 ,  A61K39/39

CPC classification number: A61K39/0005 ,  A61K39/0007 ,  A61K39/39

Abstract: Copolymer 1, a Copolymer 1-related peptide, a Copolymer 1-related polypeptide, and T cells activated therewith are useful in methods and compositions for treatment of psychiatric disorders, diseases and conditions.

Abstract translation: 共聚物1，共聚物1相关肽，共聚物1相关多肽和活化的T细胞可用于治疗精神疾病，疾病和病症的方法和组合物。

公开(公告)号：US20160208246A1

公开(公告)日：2016-07-21

申请号：US14897281

申请日：2014-06-10

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

Inventor： Yoram GRONER ,  Oren BEN-AMI

IPC: C12N15/113

CPC classification number: C12N15/113 ,  A61K31/352 ,  A61K45/06 ,  C07K14/4702 ,  C12N2310/14 ,  A61K2300/00

Abstract: A method of treating a hematological malignancy associated with an altered RUNX1 activity or expression is disclosed. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent which directly downregulates an activity or expression of RUNX1, thereby treating the hematological malignancy associated with the altered RUNX1 activity or expression.

Abstract translation: 公开了治疗与改变的RUNX1活性或表达相关的血液恶性肿瘤的方法。 该方法包括向有需要的受试者施用治疗有效量的直接下调RUNX1的活性或表达的试剂，从而治疗与改变的RUNX1活性或表达相关的血液恶性肿瘤。

公开(公告)号：US09394365B1

公开(公告)日：2016-07-19

申请号：US14957065

申请日：2015-12-02

Applicant: Yeda Research and Development Co. Ltd

Inventor： Michal Eisenbach-Schwartz ,  Kuti Baruch ,  Neta Rosenzweig

IPC: A61K39/395 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K31/4155 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2818 ,  C07K2317/76 ,  A61K38/208 ,  A61K2300/00

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract translation: 一种包含活性剂的药物组合物，其引起个体中用于治疗不包括自身免疫性神经炎症性疾病，复发性多发性硬化症（RRMS）的疾病，病症，病状或损伤的个体的全身免疫抑制水平的降低 ）。 药物组合物用于通过包含至少两个治疗疗程的剂量方案给药，每个治疗过程依次包括治疗会话，随后是间隔期。

公开(公告)号：US20160184426A9

公开(公告)日：2016-06-30

申请号：US14249709

申请日：2014-04-10

Applicant: Yeda Research and Development Co., Ltd.

Inventor： Yechiel Shai ,  Yosef Rosenfeld ,  Neta Sal-Man

IPC: A61K39/39 ,  A61K45/06 ,  C07K7/08

CPC classification number: A61K39/39 ,  A61K38/00 ,  A61K45/06 ,  C07K7/08 ,  C07K14/705

Abstract: Peptides including an amino acid sequence of a fragment of mammalian Toll-like receptor-4 (TLR-4), analogs and derivatives thereof, and pharmaceutical compositions including these peptides. Methods for modulating a TLR-4 mediated immune response, particularly stimulating TLR-4 mediated immune response, thereby treating infectious diseases and cancer.

Abstract translation: 包括哺乳动物Toll样受体-4（TLR-4）片段的氨基酸序列，其类似物及其衍生物的肽和包括这些肽的药物组合物。 用于调节TLR-4介导的免疫应答的方法，特别是刺激TLR-4介导的免疫应答，从而治疗感染性疾病和癌症。

公开(公告)号：US20160166582A1

公开(公告)日：2016-06-16

申请号：US15050502

申请日：2016-02-23

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irina LAVELIN ,  Varda ROTTER ,  Moshe OREN ,  Ami NAVON ,  Zvi KAM ,  Benjamin GEIGER

IPC: A61K31/555 ,  G01N33/50 ,  C07K14/47 ,  A61K31/522 ,  A61K31/47

CPC classification number: A61K31/555 ,  A61K31/47 ,  A61K31/52 ,  A61K31/522 ,  A61K31/60 ,  A61K33/34 ,  C07K14/4746 ,  C07K2319/40 ,  C07K2319/60 ,  C12N9/6421 ,  C12Y304/25001 ,  G01N33/5035

Abstract: A method of treating a disease in which inhibiting of a proteasome is advantageous is provided. The method comprises administering to the subject a therapeutically effective amount of a compound which binds to a proteasome of a cell, the compound comprising a copper bound to a ligand, the ligand being configured such that upon binding to the proteasome, the copper interacts with cysteine 31 of a Beta2 subunit of the proteasome and further interacts with cysteine 118 of a Beta3 subunit of the proteasome, thereby treating the disease. Additional novel proteasome inhibitors are also provided as well as methods of identifying proteasome inhibitors.